1
2
3
4
5
Hazenberg, Bouke P. C., Croockewit, Alexandra, van der Holt, Bronno, Zweegman, Sonja, Bos, Gerard M. J., Delforge, Michel, Raymakers, Reinier A. P., Sonneveld, Pieter, Vellenga, Edo, Wijermans, Pierre W., von dem Borne, Peter A., van Oers, Marinus H., de Weerdt, Okke, Spoelstra, Fokje M., Lokhorst, Henk M.
Veröffentlicht in: Hazenberg , B P C , Croockewit , A , van der Holt , B , Zweegman , S , Bos , G M J , Delforge , M , Raymakers , R A P , Sonneveld , P , Vellenga , E , Wijermans , P W , von dem Borne , P A , van Oers , M H , de Weerdt , O , Spoelstra , F M , Lokhorst , H M & Dutch-Belgian Cooperative Trial Gr 2015 , ' Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology ' , Haematologica , vol. 100 , no. 5 , pp. 677-682 . https://doi.org/10.3324//haematol.2014.119198;
2015
Veröffentlicht in: Hazenberg , B P C , Croockewit , A , van der Holt , B , Zweegman , S , Bos , G M J , Delforge , M , Raymakers , R A P , Sonneveld , P , Vellenga , E , Wijermans , P W , von dem Borne , P A , van Oers , M H , de Weerdt , O , Spoelstra , F M , Lokhorst , H M & Dutch-Belgian Cooperative Trial Gr 2015 , ' Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology ' , Haematologica , vol. 100 , no. 5 , pp. 677-682 . https://doi.org/10.3324//haematol.2014.119198;
2015
6
7
Wolters, Sharon, Carpay, Johannes A., Pronk, Marja H., Zuurbier, Karin W.M., Driessen, Maurice T., Lyras, Leonidas, Postma, Maarten J.
Veröffentlicht in: Wolters , S , Carpay , J A , Pronk , M H , Zuurbier , K W M , Driessen , M T , Lyras , L & Postma , M J 2024 , ' A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy ' , BMC NEUROLOGY , vol. 24 , no. 1 , 214 . https://doi.org/10.1186/s12883-024-03697-x;
2024
Veröffentlicht in: Wolters , S , Carpay , J A , Pronk , M H , Zuurbier , K W M , Driessen , M T , Lyras , L & Postma , M J 2024 , ' A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy ' , BMC NEUROLOGY , vol. 24 , no. 1 , 214 . https://doi.org/10.1186/s12883-024-03697-x;
2024
8
9
10